Company news

Novartis AG news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Novartis AG Enterprise Technology Report 2025: Digital Transformation Strategies, Innovation Programs, Technology Initiatives, Partnerships, Investment & Acquisition, Network Map

February 25, 2026

New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer

February 24, 2026

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

February 23, 2026

Radioligand Therapy Market to Surge with 13.1% CAGR: Projected Growth from $2.6B in 2025 to $4.8B by 2030 - Novartis' Pluvicto and Lutathera Have Catalyzed Commercial Momentum

February 19, 2026

Unnatural Products Announces Licensing Agreement with Novartis to Develop Macrocyclic Peptide Therapeutics

February 18, 2026

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

February 18, 2026

Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight

February 17, 2026

Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy

February 13, 2026

Niowave and Novartis Enter Global Actinium-225 Supply Agreement to Advance Next-Generation Cancer Therapies

February 11, 2026

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

February 6, 2026

Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025

February 4, 2026

NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX: "Relax, It's a Blood Test"

January 29, 2026

Davos Spotlight | EVYD, Ministry of Health Brunei Darussalam and Novartis Foundation Launch National AI-Powered Cardiovascular Disease Prevention Initiative

January 27, 2026

Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 in Patients with Elevated Lp(a)

January 25, 2026

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

January 16, 2026

Zonsen PepLib Biotech and Novartis Sign Worldwide License Agreement regarding Radioligand Therapy Asset

January 13, 2026

SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer's Disease

January 12, 2026

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

January 9, 2026

BizClik Launches January 2026 Sustainability Portfolio With Insights From Novartis and Amazon

January 8, 2026

Novartis and US government reach agreement on lowering drug prices in the US

December 19, 2025

Novartis breaks ground on flagship manufacturing hub in North Carolina

December 12, 2025

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

December 9, 2025

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

December 9, 2025

Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases

December 9, 2025

Opterion Health AG Announces Appointment of Andreas Schuh as Chief Financial Officer

December 1, 2025

Novartis Canada Welcomes Dimitri Gitas as New Country President

November 25, 2025

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

November 25, 2025

Muscular Dystrophy Association Calls FDA Approval of Novartis’ Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community

November 24, 2025

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

November 24, 2025

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

November 20, 2025

Novartis announces plans to build flagship manufacturing hub in North Carolina

November 19, 2025

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance

November 12, 2025

Sickle Cell Disease Treatment Market Research Report 2025 Featuring Novartis, Pfizer, Bluebird Bio, GlycoMimetics, Emmaus Medical, BMS, CRISPR Therapeutics, Graphite Bio

November 11, 2025

Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan

November 10, 2025

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

November 6, 2025

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

November 4, 2025

Meharry and Novartis Partner on HEART Initiative for Healthier Communities

November 3, 2025

Breckenridge announces launch of Everolimus Tablets, 1mg, generic version of Zortress®

October 30, 2025

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

October 29, 2025

Novartis completes acquisition of Tourmaline Bio

October 28, 2025

Novartis announces expiration of Tourmaline Bio tender offer

October 28, 2025

Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance

October 28, 2025

CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu®

October 27, 2025

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

October 26, 2025

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

October 25, 2025

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

October 22, 2025

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer

October 22, 2025

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

October 21, 2025

PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer

October 19, 2025

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population

October 17, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 39 decks. Every deck is listed under its year.